212Pb-DOTAMTATE
1 abstract
Abstract
Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.Org: Excel Diagnostics Nuclear Oncology Center, RadioMedix Inc., Orano Med SAS,